New molecular target identified in high-risk neuroblastoma

We’re excited to share the latest publication, led by Lisa Werr at the Department of Translational Genomics and Matthias Fischer, Head of Experimental Pediatric Oncology at the Uniklinik Köln.

The paper, “Mutated FGFR1 is an oncogenic driver and therapeutic target in high-risk neuroblastoma,” has just been published in the Journal of Clinical Investigation (JCI).

The study demonstrates that the FGFR1 N546K mutation is associated with a particularly aggressive form of neuroblastoma. The findings further indicate that FGFR-targeted therapies could represent a promising treatment option for patients with FGFR1-mutated tumors.

Congratulations to Lisa, Matthias and all co-authors and collaborators whose dedication made this work possible!
 

Publication: 
https://www.jci.org/articles/view/189152